ERBB2 and breast cancer: Trastuzumab is predominantly used in the treatment of the ErbB2-positive breast cancer subtype where its combination with conventional chemotherapy, had a significant effect on disease free survival of patients with early stage ErbB2+ breast cancer (Hudis, 2007).